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ABSTRACT
A 22-year-old woman with cystic fibrosis (CF) developed lung abscess, as a rare complication 
caused by multidrug-resistant (MDR) Acinetobacter baumannii infection, after lung transplan-
tation (LT). After 6 months of long-term antibiotic therapy, the abscess was successfully elimi-
nated. In reviewed published literature, no previous report was found describing this kind of 
complication caused by MDR A. baumannii in post-LT patient with CF. In our experience, lung 
abscess in LT recipients with CF can be successfully treated with prolonged antibiotic therapy.
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INTRODUCTION
Lung transplant (LT) recipients are at increased risk for both community-acquired and nosocomial pathogens, 
which may develop at various time points. 
Bacterial infection is one of the most serious 
complications in LT recipients and a signifi-
cant determinant of the transplant outcome, 
with bacterial pneumonias being the leading 
cause in this category. However, lung abscess 
is an extremely rare complication according to 
recent medical literature. Herein, we report on 
a case of multidrug-resistant (MDR) Acineto-
bacter baumannii and Pseudomonas aeruginosa 
infection presenting with lung abscess in a LT 
recipient with cystic fibrosis (CF). 
CASE REPORT
A 22-year-old woman diagnosed with CF at 
the age of three years entered end-stage lung 
disease in 2011, aged 16. She had frequently 
been admitted to hospital due to lung disease 
exacerbations and treated with various anti-
biotics leading to rapid decrease in her FEV1 
(30% from a baseline of 64%). Three years 
later, in January 2014, she was registered for 
LT program in Adult Cystic Fibrosis Centre. 
While waiting for the LT, in July 2014 the pa-
tient presented with right-sided pneumotho-
rax, which recurred four months later. In be-
tween, she had been admitted to hospital many 
times due to exacerbations of her CF. Her lung 
function continued to decrease rapidly reach-
ing an FEV1 of only 19.7%.
A double LT under ECMO support was per-
formed on January 17, 2015 in AKH Wien. 
The postoperative course was prolonged due 
to a reperfusion edema with the need for con-
tinuous ECMO support and complicated with 
MDR A. baumannii and P. aeruginosa infec-
tions. Computed tomography (CT) of the 
chest revealed two abscesses on the left lung, 
one in pleural cavity and another in the lung 
parenchyma.
The lung abscess was drained with a pigtail 
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catheter and antibiotic therapy was initiat-
ed—colistin and piperacillin/tazobactam in-
travenously (iv) with tobramycin inhalations. 
The treatment led to significant reduction of 
the abscess cavity so after 10 days the pigtail 
catheter was removed. On March 26, 2015 
she was transferred to our Department where 
she remained until April 24, 2015 (Fig 1A) 
continuing the above-mentioned antibiotics 
treatment along with frequent microbiologi-
cal surveillance. She participated in our pul-
monary rehabilitation program. By the end of 
the hospital stay her lung function was inclin-
ing. After 30 days, iv antibiotic treatment was 
replaced with colistin and tobramycin inhala-
tions. Regression in lung abscess dimensions 
was observed (Fig 1B). In October 2015, con-
trol bronchoscopy failed to reveal an MDR A. 
baumannii and P. aeruginosa infection. There-
fore, the antibiotic therapy that had lasted for 
six months, was discontinued. A few control 
chest CT scans were done. The last CT in Oc-
tober 2015 showed complete resolution of the 
abscess (Fig 1C). One year after the surgery, 
in March 2016, the patient was in a good con-
dition with satisfactory lung function (FEV1 
of 64.8%), receiving standard therapy for CF 
patients after LT (Fig 1D).
DISCUSSION
Improvements in the treatment of CF have 
delayed but not stopped the disease progres-
sion. Due to significantly extended survival 
and improved quality of life, LT has become 
a viable treatment option in patients with CF. 
The most common and serious complications 
Figure 1: CT scans of the lung abscess regression over the treatment period. A) Lung ab-
scess of the left lung after two months of beginning of the treatment (4/2015). B) Beginning 
of abscess resolution (7/2015). C) Complete resolution of the abscess (10/2015). D) Intratho-
racic status a year after the treatment (3/2016).
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after LT in these patients are graft rejection 
and infection (non-cytomegalovirus). In addi-
tion to pneumonia, which is the most common 
type of infection, other infections include em-
pyema, sepsis, and wound infection [1]. One 
of the less often complications is lung abscess. 
LT recipients, especially those with CF [2, 
3], are at increased risk for infectious compli-
cations due to the high level of immunosup-
pression required to prevent rejection, adverse 
effects of transplantation on local pulmonary 
host defense (reduced mucociliary clearance, 
decreased cough), and constant environmen-
tal contact allowing pathogens direct access 
into the allograft. Furthermore, these patients 
remain at increased risk for infection because 
the native upper airways and sinuses retain 
the chloride channel defect and remain persis-
tently colonized with the pathogens that were 
present pre-transplantation.
Infections generally occur in a predictable pat-
tern of three stages: the first month, second to 
sixth month, and after six months. During the 
first month, bacterial infections predominate 
and are typically caused by hospital-acquired 
bacteria. This categorization is not absolute 
and infections may be distributed among al-
ternative periods.
Patients with CF are more likely to be colo-
nized with nosocomial MDRs, especially with 
P. aeruginosa and Burkholderia cepacia [4] 
among other pathogens, which are associated 
with the length of intensive care unit (ICU) 
stay and previous exposure to broad-spectrum 
antibiotics.
Lung abscess caused by MDR A. baumannii is a 
complication of LT that has not been reported 
before. There is no study that can tell us which 
bacteria predominate in LT recipients with 
CF. There are some case reports, none of them 
describing abscess as a complication in LT re-
cipients caused by MDR A. baumannii. So far, 
only one case of disseminated B. gladioli infec-
tion was described characterized by bactere-
mia, necrotizing pneumonia, lung abscess and 
empyema in a patient with CF following LT. 
Due to misidentified microorganism at the 
start of the treatment, the outcome was lethal 
[5]. Therefore, it is of utmost importance to 
identify the causative microorganism to deter-
mine its significance and pathogenicity. This 
depends on multiple factors including the type 
of species isolated, colony count, and clinical 
manifestations.
To the best of our knowledge, there are no 
reports of prolonged antibiotic therapy in a 
patient suffering from lung abscess caused by 
MDR A. baumannii after LT recipient with CF.
No treatment recommendation has been is-
sued by major societies specifically for treat-
ing lung abscess as an early complication in 
LT recipients with CF caused by the MDR A. 
baumannii. In general, the antibiotic treatment 
of lung abscess is guided by the microbiol-
ogy sensitivity report. Although duration of 
therapy is not well established, most clinicians 
generally prescribe antibiotics for 4–6 weeks. 
Lung abscess may necessitate drainage with 
invasive techniques (percutaneous, endoscopic 
or surgical) along with either intravenously or 
inhalatory antibiotic treatment. We believe in 
LT recipient with CF, it is advisable to com-
bine administration of iv antibiotics (guided 
by the microbiology sensitivity report) and 
percutaneous catheter drainage of the abscess 
(in case of large lesions) with inhalatory anti-
biotic therapy.
Antibiotic treatment should be prolonged un-
til the chest radiograph has shown resolution 
of the abscess (the treatment may then take for 
several months). With evaluation and inclin-
ing of patient’s respiratory status, the patient 
may be treated on an outpatient basis for com-
pletion of long-term therapy.
There are no guidelines for postoperative 
management of bacterial infections in LT 
patients, resulting in significant variability 
among centers concerning antimicrobial pro-
phylaxis, diagnostic strategies and therapeu-
tic management. A detailed knowledge of lo-
cal epidemiology is considered to be essential 
to ensure effective management of infections, 
particularly in the ICU. This task is becom-
ing increasingly challenging with the emer-
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gence of MDR microorganisms. The goal of 
LT in all patients is to prolong survival and 
to improve the quality of life; therefore, it is 
advisable to have an effective strategy in deal-
ing with complications of LT, primarily post-
transplantation infections. Here, a case of suc-
cessful treatment of rare complication (lung 
abscess) has been presented. With long-term 
antibiotic regimen we succeeded to eliminate 
infection and cure the patient.
Since no guidelines or recommendations on 
antibiotic regimen duration exist, this case 
report could help direct the clinicians when 
treating rare complications of LT such as lung 
abscess in patients with CF.
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